Page 80 - ISALUD Número 71 - Marzo2020

care physicians in West Virginia. W V Med J, 108 (3), 30-35. familial hypercholesterolaemia using alternative diagnostic and identifi-
– Kavey RE, D. S. (2003). American Heart Association guidelines for primary cation strategies. Heart, 97 (14), 1175-1181.
prevention of atherosclerotic cardiovascular disease beginning in child- – O’Loughlin J, L. B. (2004). Usefulness of the American Academy of Pedia-
hood. Circulation (107), 1562-1566. trics recommendations for identifying youths with hypercholesterolemia.
– Kerr M, P. R. (2017). Cost effectiveness of cascade testing for familial hy- Pediatrics, 113, 1723-1727.
percholesterolaemia, based on data from familial hypercholesterolaemia – Office for National Statistics (2004). Obtenido de ONS (1998) Mortality
services in the UK. Eur Heart J, 1832-1839. Statistics – Cause (DH2 No. 24), Stationery Office: London: https://www.
– Kusters DM, A. H. (2014). Ten-year follow-up after initiation of statin the- ons.gov.uk/ons/.../mortality-statistics--cause...dh2.../mortality-statistics-
rapy in children with familial hypercholesterolaemia. JAMA, 312, 1055- -caus...
1057. – Oliva, J., Moreno , S. G., & Mata , P. (2009). Cost-effectiveness analysis
– Kusters DM, W. A. (2014). Carotid intima-media thickness in children with of a genetic screening program in the close relatives of Spanish patients
familial hypercholesterolaemia. Circ Res, 114, 307-310. with familial hypercholesterolemia. Rev Esp Cardiol, 62 (1), 57-65.
– Lázaro P, P. d.-M.-J.-D. (2017). Cost-effectiveness of a cascade screening – Pelczarska A, J. M.-L. (2018). The cost-effectiveness of screening strate-
program for the early detection of familial hypercholesterolemia. 11(1): J gies for familial hypercholesterolaemia in Poland. Atherosclerosis , 270,
Clin Lipidol, 11 (1), 260-271. 132-138.
– Louter L, D. J. (2017). Cascade screening for familial hypercholesterole- – Prades, J. P. (2003). Métodos para la evaluación económica de nuevas
mia: Practical consequences. Atheroscler, 30, 77-85. prestaciones. Barcelona: Ministerio de Sanidad y Consumo.
– Lozano P, H. N. (Aug de 2016). Lipid Screening in Childhood and Ado- – Rosso A, P. E. (2017). The Cost-effectiveness of Genetic Screening for
lescence for Detection of Familial Hypercholesterolemia: A Systematic Familial Hypercholesterolemia: a Systematic Review. Ann Ig, 29 (5), 464-
Evidence Review for the U.S. Preventive Services Task Force [Internet] 480.
Agency for Healthcare: http://www.ncbi.nlm.nih.gov/books/NBK379718. – Scientific Steering Committee on behalf of the Simon Broome Register
– Mabuchi H, K. J. (1989). Development of coronary heart disease in familial Group (1999). Mortality in treated heterozygous familial hypercholestero-
hypercholesterolemia. Circulation, 79, 225-232. lemia: implications for clinical management. Atherosclerosis (142), 105-
112.
– Marang-van de Mheen, P. J., Bonneux, L., Bonsel, G. J., & Klazinga, N. S.
(2002). Cost-effectiveness of a family and DNA based screening program- – Scientific Steering Committee on behalf of the Simon Broome Register
me on familial hypercholesterolemia in The Netherlands. Eur Heart J, 23 Group (1991). Risk of fatal coronary heart disease in familial hypercholes-
(24), 1922-1930. terolemia. BMJ, 303, 893-896.
– Marks, D., Thorogood, M., HAW, N., & Wonderling, D. (2003). Comparing – Skovby F, M. S. (1991). Screening for familial hypercholesterolaemia by
costs and benefits over a 10 year period of strategies for familial hyper- measurement of apolipoproteins in capillary blood. Arch Dis Child, 66 (7),
cholesterolaemia screening. J Public Health Med, 25 (1), 47-52. 844-847.
– Marks, D., et al. (2000). Screening for hypercholesterolemia versus case – Stempel H, D. A. (2016). Referral Patterns and Cascad Screening for
finding for familial hypercholesterolemia: a systematic review and cost- Familial Hypercholesterolemia in a Pediatric Lipid Clinic. J Pediatr, 178,
effectiveness analysis. Health Technology Assessment, 4 (29). 285-287.
– Marks, D., Wonderling, D., & Thorogood, M. (2002). Cost effectiveness – Tsevat J, G. L. (1993). Stability of time-tradeoff utilities in survivors of
analysis of different approaches of screening for familial hypercholeste- myocardial infarction. Med Decis Making, 13 (2), 161-165.
rolaemia. Br Med J, 324 (7349), 1303-1306. – Urbina EM, d. F. (2016). Lipid Screening in Children and Adolescents.
– McCrindle BW, G. S. (2016). Hypercholesterolemia? N Engl J Med, 375 JAMA. , 316 (6), 589-591.
(17), 1685-1686. – Valle CW, B. H.-S. (2015). Physicians’ Lack of adherence to National Heart,
– McCrindle BW, U. E. (2007). Drug therapy of high-risk lipid abnormalities Lung and Blood Institute Guidelines for Pediatric Lipid Screening. Clin Pe-
in children and adolescents: a scientific statement from the American diatr (Phila), 54 (12), 1200-1205.
Heart Association Atherosclerosis, Hypertension, and Obesity in Youth – Wald DS, B. J. (2016). Child-Parent Familial Hypercholesterolemia Scree-
Committee, Council of Cardiovascular Disease in the Young, with the. Cir- ning in Primary Care. N Engl J Med, 375 (17), 1628-1637.
culation, 115, 1948-1967. – Wald DS, B. J. (2007). Child-parent screening for familial hypercholestero-
– McGill HC Jr, M. C. (1998). Determinants of atherosclerosis in the young. laemia: screening strategy based on a meta-analysis. BMJ. , 335 (7620),
Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research 599.
Group. Review. Am J Cardiol, 82 (10B), 30T-36T. – Ward S, L. J. (2005). Statins for the Prevention of Coronary Events: Te-
– Melsop KA, B. D. (2003). Quality of life and time trade-off utility measures chnology assessment report commissioned by the HTA Programme on
in patients with coronary artery disease. American Heart Journal, 145 (1), behalf of the National Institute for Clinical Excellence. London: National
36-41. Institute for Health and Clinical Excellence.
– NCCP. (2008). A model to estimate the cost-effectiveness of higher versus – Wonderling, D., Umans-Eckenhausen, M. A., & Marks, D. (2004). Cost-
lower intensity statins in the treatment of coronary heart disease. Lipid effectiveness analysis of the genetic screening program for familial hy-
modification: cardiovascular risk assessment and the modification of percholesterolemia in The Netherlands. Semin Vasc Med, 4 (1), 97-104.
blood. London: National Collaborating Centre for Primary Care. – Yusuf S, H. S. (2004). Effect of potentially modifiable risk factors associa-
– Nherera, L., Marks, D., Minhas, R., Thorogood, M., & Humphries, S. E. ted with myocardial infarction in 52 countries (the INTERHEART study):
(2011). Probabilistic cost-effectiveness analysis of cascade screening for case-control study. Lancet , 364, 937-952.

80